Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Research Reveals Disconnect Between Parents and Physicians in Pediatric Clinical Trial Recruitment

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Study from Blue Chip Patient Recruitment provides best practices for recruiting pediatric patients in clinical trials.

Blue Chip Patient Recruitment, a global, full-service strategic marketing practice of Blue Chip Marketing Worldwide that specializes in accelerating enrollment of clinical trials, has announced results of its latest research study on how physicians and clinical trial coordinators can successfully accelerate enrollment of pediatric clinical trials.

The white paper, titled “Accelerating Recruitment for Pediatric Clinical Trials: Connecting Parents, Children and Investigators” and available at www.bcpatientrecruitment.com/whitepaper, summarizes the results of primary market research that explores the motivations and barriers a parent faces when considering clinical trial opportunities for their child and the challenges physicians experience when recruiting children for clinical trials.

“Understanding the true motivations and worries behind a parent’s decision to enroll their child in a clinical trial is essential for successful enrollment,” says Neil Weisman, EVP/general manager of Blue Chip Patient Recruitment. “With adult conditions starting to emerge in children more frequently and since many medications have never been studied in children, sponsors and investigators will need this type of research to successfully address changing pediatric healthcare needs.”

Key findings include:

The study shows that even though parents may be very or somewhat satisfied with their child’s current medication, physicians should always educate and inform parents of potential clinical trial opportunities. Nearly 85% of the parents who were “very or somewhat satisfied” with their child’s current medication indicated they would be willing to switching their child to a new medication option.

To better connect with parents, physicians should focus on how the trial can potentially benefit their child as opposed to more altruistic-based communications. More than 53% of parents cited “my child might benefit” as their top motivation for enrolling their child in a clinical trial while 74% of physicians chose “benefit other children in the future” as their main point when educating parents on clinical trial opportunities.

Physicians need to understand and create communications based on how their patients’ parents prefer to receive information about potential pediatric clinical trial opportunities. Listed as the most preferred method of communications, 46% of parents indicated they prefer to receive information about pediatric clinical trial opportunities from their physicians by email, whereas only 6% of physicians stated that email was the most effective way to communicate with parents. And while not one doctor stated a physical letter was effective, nearly 30% of parents preferred to receive clinical trial information via a physical letter.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!